Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) Non-Current Deffered Revenue: 2017-2018

Historic Non-Current Deffered Revenue for Astria Therapeutics (ATXS) over the last 2 years, with Dec 2018 value amounting to $9,000.

  • Astria Therapeutics' Non-Current Deffered Revenue fell 89.89% to $9,000 in Q4 2018 from the same period last year, while for Dec 2018 it was $9,000, marking a year-over-year decrease of 89.89%. This contributed to the annual value of $9,000 for FY2018, which is 89.89% down from last year.
  • Latest data reveals that Astria Therapeutics reported Non-Current Deffered Revenue of $9,000 as of Q4 2018, which was down 83.64% from $55,000 recorded in Q3 2018.
  • In the past 5 years, Astria Therapeutics' Non-Current Deffered Revenue registered a high of $97,000 during Q3 2017, and its lowest value of $9,000 during Q4 2018.
  • Over the past 2 years, Astria Therapeutics' median Non-Current Deffered Revenue value was $74,000 (recorded in 2018), while the average stood at $61,714.
  • Examining YoY changes over the last 5 years, Astria Therapeutics' Non-Current Deffered Revenue showed a top increase of 215.38% in 2018 and a maximum decrease of 89.89% in 2018.
  • Quarterly analysis of 2 years shows Astria Therapeutics' Non-Current Deffered Revenue stood at $89,000 in 2017, then tumbled by 89.89% to $9,000 in 2018.
  • Its Non-Current Deffered Revenue was $9,000 in Q4 2018, compared to $55,000 in Q3 2018 and $74,000 in Q2 2018.